Compare Bristol-Myers Squibb Co (BMY) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Grab Holdings Ltd. — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Grab Holdings Ltd. trades at $3.78 (market cap $15.54B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.5× Grab Holdings Ltd.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| BMY | GRAB | |
|---|---|---|
Market Cap | $116.30B | $15.54B |
Sector | Health | Technology |
52-Week High | $62.37 | $6.45 |
52-Week Low | $42.60 | $3.27 |
Enterprise Value | $152.24B | $11.23B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GRAB trades at $3.94, up 0.25% on the day, with a bullish technical signal and strong analyst support. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from prior losses. Revenue growth continues, reaching $3.37B in 2025. Recent news highlights market outperformance and investor attention, though the stock reacted negatively to Uber CEO's board departure in early July 2026.
Outlook remains positive with 91.67% analyst buy ratings and $5.45 consensus target, implying 38% upside. Key risks include competitive pressures in ride-hailing, execution challenges in expanding financial services, and potential market volatility. Profitability trajectory and cash flow sustainability are critical for maintaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
